Chemistry:Ranimustine
From HandWiki
Ranimustine (INN, marketed under the tradename Cymerin; also known as MCNU) is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemia[1] and polycythemia vera.[2]
It has never been filed for FDA evaluation in the United States, where it is not marketed.
Synthesis
- upright=2
Ranimustine is made by reacting the primary amine of a pyranose sugar (2) with o-nitrophenyl N-(2-chloroethyl)-N-nitrosocarbamate (1) to form the nitrosourea group.[3] [4]
References
- ↑ "[Chemotherapy of chronic myelogenous leukemia--VP(M) regimen initiated during its chronic phase, and evaluation of MCNU in the phase of blastic crisis]" (in ja). Gan to Kagaku Ryoho. Cancer & Chemotherapy 16 (11): 3573–3579. November 1989. PMID 2817908.
- ↑ "[Therapeutic effect of ranimustine (MCNU) on essential thrombocythemia and polycythemia vera]" (in ja). Gan to Kagaku Ryoho. Cancer & Chemotherapy 15 (12): 3267–3270. December 1988. PMID 3196045.
- ↑ Goro Kimura, "Process for producing glucopyranose-nitrosourea compounds and novel compounds included therein", US patent 4156777, issued 1979-05-29, assigned to Tokyo Tanabe Co Ltd
- ↑ "In the search for new anticancer drugs. XXIII: Exploration of a predictive design for anticancer drugs of carbohydrates containing N-nitrosochloroethylamino, N-nitrosomethyl, and N-nitrosoaminoxyl components". Journal of Pharmaceutical Sciences 80 (7): 693–699. July 1991. doi:10.1002/jps.2600800717. PMID 1658297.
External links
- (in Japanese) Cymerin サイメリン (PDF) Mitsubishi Tanabe Pharma. October 2007.
 |  |
